Sepracor shifts Lunesta DTC biz

Share this article:

Sepracor has shifted its Lunesta DTC advertising business from McCann Erickson to Kaplan Thaler Group.

Since 2006, ads featuring Lunesta's moth have ranked tops in viewer recall, according to IAG Research, and Sepracor leads the industry in DTC spending as a result of its hefty outlays on the brand's behalf. From January 2006 through September 2007, Lunesta DTC spend totaled nearly $453 million, according to TNS Media Intelligence. By contrast, Sanofi-Aventis spent a scant $265 million on consumer ads for its Ambien franchise, and Takeda spent a paltry $171 million promoting Rozerem to consumers. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?